Schonfeld Strategic Advisors LLC Increases Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Schonfeld Strategic Advisors LLC grew its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 1,960.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 533,643 shares of the company's stock after acquiring an additional 507,743 shares during the quarter. Schonfeld Strategic Advisors LLC owned 0.21% of Maravai LifeSciences worth $2,908,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Barclays PLC grew its position in Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company's stock worth $1,531,000 after purchasing an additional 143,184 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of Maravai LifeSciences during the third quarter valued at $600,000. JPMorgan Chase & Co. increased its position in shares of Maravai LifeSciences by 1,172.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company's stock valued at $33,658,000 after acquiring an additional 3,731,924 shares during the period. FNY Investment Advisers LLC increased its position in shares of Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock valued at $38,000 after acquiring an additional 6,000 shares during the period. Finally, SG Americas Securities LLC raised its stake in Maravai LifeSciences by 7.3% in the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company's stock worth $180,000 after acquiring an additional 2,239 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Trading Down 3.9 %

Shares of NASDAQ MRVI traded down $0.08 during midday trading on Friday, reaching $1.99. 2,210,332 shares of the stock were exchanged, compared to its average volume of 2,349,935. The stock has a market capitalization of $506.13 million, a P/E ratio of -1.21 and a beta of 0.19. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The company has a 50 day simple moving average of $2.19 and a 200 day simple moving average of $4.27. Maravai LifeSciences Holdings, Inc. has a twelve month low of $1.67 and a twelve month high of $11.56.

Analyst Ratings Changes

Several analysts have weighed in on MRVI shares. Baird R W downgraded Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a report on Friday, March 21st. Robert W. Baird downgraded shares of Maravai LifeSciences from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $9.00 to $3.00 in a report on Wednesday, February 26th. UBS Group lowered their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Finally, Morgan Stanley decreased their price target on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of "Hold" and an average price target of $6.34.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.